Please ensure Javascript is enabled for purposes of website accessibility


Big things are happening at Ogier. Change is embedded in everything we do. It is redefining our talent, our ways of working, our platforms of delivery, our culture.



We have the expertise to handle the most demanding transactions. Our commercial understanding and experience of working with leading financial institutions, professional advisers and regulatory bodies means we add real value to clients’ businesses.

View all services


Our experts provide independent guidance spanning advice and training to implementation and evaluation across sustainable investing, regulatory compliance and tech. Our tailored advice meets clients' specific needs, delivering flexible solutions and support.

View all Consulting

Business Services Team

View all Business Services Team


Our sector approach relies on smart collaboration between teams who have a deep understanding of related businesses and industry dynamics. The specific combination of our highly informed experts helps our clients to see around corners.

View all sectors


Ogier provides practical advice on BVI, Cayman Islands, Guernsey, Irish, Jersey and Luxembourg law through our global network of offices across the Asian, Caribbean and European timezones. Ogier is the only firm to advise on this unique combination of laws.

News and insights

Keep up to date with industry insights, analysis and reviews. Find out about the work of our expert teams and subscribe to receive our newsletters straight to your inbox.

Fresh thinking, sharper opinion.

About us

We get straight to the point, managing complexity to get to the essentials. Our global network of offices covers every time zone. 

No Content Set

Cayman team advises on 350 million Arya SPAC merger with biotech start-up


11 February 2021

Cayman Islands

2 min read

Ogier's Cayman Islands team has advised on Arya Sciences Acquisition Corp III's business combination with Nautilus Biotechnology.

Nautilus, a pioneering start-up mapping human proteins, is expected to receive $350 million in proceeds through the merger with Arya III, a special purpose acquisition company (SPAC) sponsored by Perceptive Advisors. This includes a $200 million fully committed PIPE led by Perceptive Advisors and other top-tier healthcare investors.

As a result of the business combination, Arya III will re-domicile as a Delaware corporation and be renamed Nautilus Biotechnology Inc, and its common stock is expected to be listed on Nasdaq under the ticker symbol NAUT.

The transaction values Nautilus Biotechnology Inc at an implied equity value of $900 million and the combined company is expected to have an initial market capitalization of approximately $1.3 billion.

Ogier's team was led by partner Angus Davison.

Angus said: "This was a significant transaction for Arya and we're very happy to have worked on it with them. The growing popularity of SPACS looks set to continue into 2021 and Ogier's global equity capital markets team has demonstrated significant experience in advising on the establishment and the listing of SPACS, as well as advising on their subsequent business combination transactions."

No Content Set